Medical Marijuana Reclassified to Schedule III
The Trump administration reclassified medical marijuana from Schedule I to Schedule III, easing research barriers and providing tax relief to licensed operators.
Objective Facts
Under President Trump's administration, the Department of Justice reclassified state-licensed medical marijuana from Schedule I to Schedule III drug under the Controlled Substances Act, a policy shift that does not legalize cannabis at the federal level but represents a significant change in how marijuana is regulated, studied, and potentially integrated into clinical and research settings. The order signed by Acting Attorney General Todd Blanche places FDA-approved products containing marijuana and products regulated by a state medical marijuana license in Schedule III. The action could facilitate new research on medicinal uses and make the marijuana industry more profitable. Marijuana that's sold for recreational purposes — even in states that legally allow it — will remain a Class I drug under the order.
Left-Leaning Perspective
Adam J. Smith, executive director of the Marijuana Policy Project, welcomed the Trump administration's move, calling rescheduling "a historic move towards sanity in cannabis policy" and expressing hope it will open doors to medical research and fairer tax treatment for the regulated industry. However, Smith immediately qualified his support, arguing that a move to Schedule III stops short of the systemic change needed, doing nothing to end hundreds of thousands of possession arrests each year nor fixing the untenable disconnect between federal prohibition and regulated state markets under which more than half of American adults live. Smith emphasized that despite the historic nature of rescheduling, major reforms remain to be secured, especially decriminalization, with more than 200,000 Americans arrested for cannabis-related offenses last year, and thousands of people whose lives have been "upended by an arrest for possession of a plant," noting that rescheduling is a great step but does not solve all problems.
Right-Leaning Perspective
Not all Republicans welcomed the move; Senator Thom Budd led 22 Senate Republican colleagues in opposing rescheduling, arguing it would send a confusing message about the drug's health risks, while Smart Approaches to Marijuana retained former Attorney General Bill Barr to challenge the order in court. Kevin Sabet, president of Smart Approaches to Marijuana, contended that "today's marijuana is more dangerous than previously thought, not less dangerous" and that the drug should be "carefully researched, of course, but not legalized through the backdoor". Sabet characterized the marijuana industry as "the new Big Tobacco" and stated there are "many ways to increase our knowledge without giving a tax break to Big Weed and sending a confusing message about marijuana's harms to the American public". Sen. Tom Cotton pushed back immediately, writing that "marijuana today is much more potent than just ten or twenty years ago, leading to increased psychosis, anti-social behavior, and fatal car crashes," calling the reclassification "a step in the wrong direction".
Deep Dive
The Biden administration initiated the reclassification process in 2022, with the Department of Health and Human Services concluding in August 2023 that marijuana has accepted medical use and recommending Schedule III, and the DEA publishing a proposed rule in May 2024, but the process stalled when Trump succeeded Biden and ordered the process to move as quickly as legally possible. To accelerate this, Acting Attorney General Todd Blanche used a specific legal authority—a provision allowing the attorney general to classify drugs the U.S. must regulate under international treaty obligations—to bypass the stalled DEA rulemaking process entirely, terminating the Biden-era proceedings and starting a new hearing scheduled for June 29. The left-right split reveals genuine tension: progressives welcome reclassification as opening research and providing tax relief to compliant operators but criticize it for not addressing possession arrests or resolving the federal-state conflict, while conservatives argue the move is a "giveaway to Big Weed" that downplays marijuana's harms and that research can be advanced without tax breaks. A key procedural dispute centers on whether the Attorney General had legal authority to bypass notice-and-comment rulemaking; critics argue it violates federal law while supporters contend international treaty obligations justify the shortcut. Industry observers note that Schedule III is not a finish line or even the halfway point, but represents the first time federal policy has meaningfully moved toward acknowledging that federal prohibition was a policy failure.